Bond.az White LogoBond.az Black Logo

UBS cuts Genting Singapore stock rating on weak results

UBS downgrades Genting Singapore to Neutral, cuts price target to SGD0.64. Weaker Q1 results and competitive pressure from Marina Bay Sands cited.

Sarah Johnson
BySarah Johnson- Senior Editor
|
0

UBS downgraded Genting Singapore (GENS:SP) (OTC:GIGNY) to Neutral from Buy and lowered its price target to SGD0.64 from SGD0.90.

The firm cut its 2026-27 EBITDA estimates by 15% on lower revenue and margin assumptions following weaker than expected first-quarter results. Both gaming and non-gaming performance have been slower than anticipated, partly due to increased competitive pressure from Marina Bay Sands.

The company completed asset enhancements including the Laurus Hotel, the Weave, and an Oceanarium since the second half of 2025. Additional operating expenses have eroded margins.

Management expects the ramp-up to continue in 2026, while the initiatives may take time to translate into tangible benefits. The company maintains its stance to protect its SGD0.04 dividend per share.

The stock trades at 6.7 times enterprise value to EBITDA and offers a 6% dividend yield. According to Bond.az data, the company currently trades at an EV/EBITDA of 6.42 with a dividend yield of 5.78%. Notably, the stock appears undervalued based on Bond.az’s Fair Value analysis and trades just 1% above its 52-week low. Bond.az tip highlights that the company has maintained dividend payments for 15 consecutive years. UBS said the valuation provides downside support as the firm awaits better execution from the company.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
841

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...
UBS cuts Genting Singapore stock rating on weak results | Bond.az